J. Boos

J. Boos, W. Wohlgemuth, H. Bruijnen, 2012, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma

G. Hempel, G. Würthwein, J. Boos, 2002, Cancer Chemotherapy and Pharmacology.

Modulation of Ara-C Cytotoxicity by Coadministration with Antisignalling Drugs in HL60 and Ara-C-Resistant HL60/Ara-C Cells

A. Gescher, J. Boos, A. Freund, 1998 .

Augmentation of 1-beta-D-arabinofuranosylcytosine (Ara-C) cytotoxicity in leukaemia cells by co-administration with antisignalling drugs.

G. Peters, A. Gescher, J. Boos, 1998, European journal of cancer.

Endothelial vWf and t-PA release after incubation with different concentrations of asparaginase and dexamethasone

J. Boos, U. Nowak‐Göttl, B. Kehrel, 1996 .

Age and DNA-methylation subgroup as potential independent risk factors for treatment stratification in children with Atypical Teratoid/Rhabdoid Tumors (ATRT).

S. Bens, R. Siebert, M. Kool, 2019, Neuro-oncology.

Feasibility of Intensive Multimodal Therapy in Infants Affected by Rhabdoid Tumors – Experience of the EU-RHAB registry

R. Siebert, J. Gerss, I. Leuschner, 2014, Klinische Pädiatrie.

Therapy of childhood acute myelogenous leukemias

H. Jürgens, H. Jürgens, J. Boos, 1996, Annals of Hematology.

Determination of idarubicin and idarubicinol in plasma by capillary electrophoresis.

G. Hempel, J. Boos, G. Blaschke, 1997, Journal of chromatography. B, Biomedical sciences and applications.

Simultaneous determination of all-trans-, 13-cis- and 9-cis-retinoic acid, their 4-oxo metabolites and all-trans-retinol in human plasma by high-performance liquid chromatography.

G. Hempel, J. Boos, G. Blaschke, 1996, Journal of chromatography. B, Biomedical applications.

Bioanalysis of doxorubicin aglycone metabolites in human plasma samples–implications for doxorubicin drug monitoring

C. Lanvers-Kaminsky, G. Hempel, G. Würthwein, 2020, Scientific Reports.

Quantification of daunorubicin and daunorubicinol in plasma by capillary electrophoresis.

G. Hempel, J. Boos, P. Schulze-Westhoff, 2001, Journal of chromatography. B, Biomedical sciences and applications.

Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure

F. Berthold, N. André, C. Lanvers-Kaminsky, 2019, BMC Pharmacology and Toxicology.

Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors

C. Lanvers-Kaminsky, J. Boos, Viktor Arnhold, 2016, Cancer Chemotherapy and Pharmacology.

Continuous or repeated prolonged cisplatin infusions in children: A prospective study on ototoxicity, platinum concentrations, and standard serum parameters

C. Lanvers-Kaminsky, U. Jaehde, D. Deuster, 2006, Pediatric blood & cancer.

Cytotoxicity of dimethylacetamide and pharmacokinetics in children receiving intravenous busulfan.

C. Lanvers-Kaminsky, T. Klingebiel, B. Gruhn, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Toxicity and pharmacokinetics of i.v. busulfan in children before stem cell transplantation

T. Klingebiel, B. Gruhn, G. Hempel, 2005, Anti-cancer drugs.

Population pharmacokinetics of high-dose etoposide in children receiving different conditioning regimens

T. Klingebiel, G. Würthwein, J. Boos, 2002, Anti-cancer drugs.

Randomized clinical trials in children--ethical and methodological issues.

J. Boos, L. G. Rothenberger, A. Henschel, 2010, Current pharmaceutical design.

Unphysiological effects contributing to asparaginase toxicity in vitro.

J. Boos, A. Wagner, 1998, The American journal of physiology.

Modulation of ara-CTP levels by fludarabine and hydroxyurea in leukemic cells

J. Boos, M. Ahlmann, C. Lanvers, 2001, Leukemia.

Trofosfamide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the oral treatment of cancer.

G. Hempel, J. Boos, A. Wagner, 1997, Anti-cancer drugs.

Retinoids Modulate Ara-CTP Pharmacology in the HL-60 Acute Leukemia Cell line

H. Jürgens, J. Boos, C. Rossig, 1998 .

Pharmacology of all-trans-retinoic acid in children with acute promyelocytic leukemia.

D. Reinhardt, J. Boos, U. Creutzig, 2003, Medical and pediatric oncology.

The best way to use asparaginase in childhood acute lymphatic leukaemia – still to be defined?

J. Boos, J. P. V. Pinheiro, 2004, British journal of haematology.

Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study

M. Zucchetti, J. Gerss, M. Schrappe, 2019, Haematologica.

Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor–related apoptosis‐inducing ligand (TRAIL)

W. Winkelmann, S. Fulda, F. van Valen, 2000, International journal of cancer.

Population pharmacokinetics of liposomal daunorubicin in children.

D. Reinhardt, G. Hempel, J. Boos, 2003, British journal of clinical pharmacology.

Therapeutic drug monitoring of doxorubicin in paediatric oncology using capillary electrophoresis

G. Hempel, J. Boos, P. Schulze-Westhoff, 1998, Electrophoresis.

Dependence of Asparaginase-lnduced Coagulopathy on Serum Asparaginase Activity: A Randomized Trial

H. Jürgens, J. Boos, U. Nowak‐Göttl, 1997 .

Asparaginase decreases clotting factors in vitro: a possible pitfall?

H. Jürgens, J. Boos, H. Lill, 1995, International journal of clinical & laboratory research.

Influence of two different e.coli asparaginase preparations on coagulation and fibrinolysis: A randomized trial

H. Jürgens, J. Boos, H. Pollmann, 1994 .

Interactions of carboxypeptidase G2 with 6S-leucovorin and 6R-leucovorin in vitro: implications for the application in case of methotrexate intoxications

G. Hempel, J. Boos, R. Lingg, 2005, Cancer Chemotherapy and Pharmacology.

Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.

H. Jürgens, E. Verspohl, G. Würthwein, 1996, European journal of cancer.

Antineoplastic agent busulfan regulates a network of genes related to coagulation and fibrinolysis

U. Völker, H. Kroemer, E. Hammer, 2012, European Journal of Clinical Pharmacology.

Population pharmacokinetics of oral busulfan in children

T. Klingebiel, B. Gruhn, G. Hempel, 2003, Cancer Chemotherapy and Pharmacology.

Multidisciplinary Network ActiveOncoKids guidelines for providing movement and exercise in pediatric oncology: Consensus‐based recommendations

U. Dirksen, F. Baumann, J. Wiskemann, 2022, Pediatric blood & cancer.

Evaluation of effects of busulfan and DMA on SOS in pediatric stem cell recipients

Mirjam N Trame, G. Hempel, K. Kerl, 2014, Pediatric blood & cancer.

Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m2 PEG asparaginase in children with ALL treated according to protocol COALL‐06‐97

K. Wenner, C. Lanvers-Kaminsky, G. Escherich, 2006, Pediatric blood & cancer.

Pharmacology of PEG-asparaginase in childhood acute lymphoblastic leukemia (ALL).

G. Würthwein, J. Boos, J. P. V. Pinheiro, 2002, Blood.

Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL.

J. Boos, U. Nowak‐Göttl, E. Ahlke, 1996, Haematologica.

Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients.

H. Jürgens, J. Boos, J. Ritter, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics and Metabolism of Low-Dose ATRA in Children — First Observations

H. Jürgens, G. Würthwein, J. Boos, 1998 .

Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: Report of the HD CWS‐96 trial

T. Klingebiel, E. Koscielniak, H. Gadner, 2008, Pediatric blood & cancer.

Population pharmacokinetic approach to compare oral and i.v. administration of etoposide.

H. Jürgens, G. Würthwein, J. Boos, 1999, Anti-cancer drugs.

Population Pharmacokinetics of Liposomal Amphotericin B and Caspofungin in Allogeneic Hematopoietic Stem Cell Recipients

C. Lanvers-Kaminsky, G. Hempel, G. Würthwein, 2011, Antimicrobial Agents and Chemotherapy.

Pegylated asparaginase in combination with high‐dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study

O. Rosen, T. Ittel, J. Boos, 2003, British journal of haematology.

PEG-asparaginase (Oncaspar) 2500 U/m2 BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols

M. Schrappe, G. Henze, H. Müller, 2002, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL‐BFM 95 reinduction treatment

M. Schrappe, H. Müller, R. Beier, 2001, British journal of haematology.

Use of L-asparaginase in childhood ALL.

H. Müller, J. Boos, J Boos, 1998, Critical reviews in oncology/hematology.

Pharmacokinetic/Pharmacodynamic Monitoring of l-Asparaginase in Children

H. Jürgens, H. Jürgens, E. Verspohl, 1997 .

Changes in coagulation and fibrinolysis in childhood ALL: a two‐step dose reduction of one E. coli asparaginase preparation

J. Boos, U. Nowak‐Göttl, P. Schulze-Westhoff, 1996, British journal of haematology.

Determination of free and liposome-associated daunorubicin and daunorubicinol in plasma by capillary electrophoresis.

G. Hempel, J. Boos, G. Blaschke, 2002, Journal of chromatography. A.

Paediatric and geriatric drug delivery

Jörg Breitkreutz, J. Breitkreutz, J. Boos, 2007, Expert opinion on drug delivery.

The stability of doxorubicin and ldarubicin in plasma and whole blood

G. Hempel, G. Würthwein, J. Boos, 2000 .

Immediate Cooling Does Not Prevent the Ex Vivo Hydrolysis of L-Asparagine by Asparaginase

M. Zucchetti, C. Lanvers-Kaminsky, M. D’Incalci, 2014, Therapeutic drug monitoring.

L‐asparaginase treatment in acute lymphoblastic leukemia

C. Pui, R. Pieters, A. Baruchel, 2011, Cancer.

An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies

C. Lanvers-Kaminsky, J. Boos, K. Spaniol, 2011, Anti-cancer drugs.

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.

Christian Urban, Martin Zimmermann, Martin Stanulla, 2007, Blood.

Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia.

M. Zucchetti, J. Gerss, M. Schrappe, 2020, Haematologica.

Population pharmacokinetics of intravenous busulfan in children: revised body weight-dependent NONMEM® model to optimize dosing

G. Hempel, J. Boos, J. McCune, 2014, European Journal of Clinical Pharmacology.

Population Pharmacokinetics of Busulfan in Children: Increased Evidence for Body Surface Area and Allometric Body Weight Dosing of Busulfan in Children

Mirjam N Trame, M. Karlsson, G. Hempel, 2011, Clinical Cancer Research.

Second temporal remission in a malignant glioma with trofosfamide and etoposide: a case report.

H. Jürgens, J. Boos, J. Wolff, 1996, Klinische Padiatrie.

Preclinical Evaluation of Combined Topoisomerase and Proteasome Inhibition Against Pediatric Malignancies

C. Lanvers-Kaminsky, J. Boos, Edvin Destanovic, 2018, AntiCancer Research.

Sports in Pediatric Oncology: the Role(s) of Physical Activity for Children With Cancer

J. Boos, M. Götte, Silke Taraks, 2014, Journal of pediatric hematology/oncology.

Asparagine Synthetase in Pediatric Acute Leukemias: AML-M5 Subtype Shows Lowest Activity

J. Boos, J. Ritter, U. Creutzig, 1998 .

Carboplatin Dosing in Children: Calculation by Different Formulae

J. Gerss, G. Würthwein, J. Boos, 2011, Oncology Research and Treatment.

Monitoring of Mycophenolic Acid in the Plasma of Transplant Patients by Capillary Electrophoresis

M. Fobker, G. Hempel, G. Würthwein, 2006 .

Determination of mycophenolic acid and its glucuronide conjugate in human plasma by capillary electrophoresis

G. Hempel, J. Boos, G. Blaschke, 2001 .

High efficacy of recombinant urate oxidase in prevention of renal failure related to tumor lysis syndrome (TLS).

G. Leverger, C. Patte, J. Boos, 1998 .

Phase II study of gemcitabine in children with solid tumors of mesenchymal and embryonic origin

J. Boos, M. Paulussen, C. Stoffregen, 2006, Anti-cancer drugs.

The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro

W. Winkelmann, F. van Valen, J. Boos, 2001, Anti-cancer drugs.

Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity.

P. Voûte, U. Abel, I. Leuschner, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity.

C. Lanvers-Kaminsky, A. Sparreboom, H. Jürgens, 2015, Pharmacogenomics.

Improved 6‐year overall survival in AT/RT – results of the registry study Rhabdoid 2007

R. Siebert, J. Gerss, R. Kortmann, 2016, Cancer medicine.

Pharmacokinetics of intravenous paracetamol in children and adolescents under major surgery

G. Hempel, G. Würthwein, J. Boos, 2005, European Journal of Clinical Pharmacology.

Drug monitoring of low‐dose PEG‐asparaginase (Oncaspartm) in children with relapsed acute lymphoblastic leukaemia

G. Henze, G. Würthwein, J. Boos, 2001, British journal of haematology.

Phase II study of gemcitabine in children with relapsed leukemia

G. Henze, J. Boos, A. von Stackelberg, 2006, Pediatric blood & cancer.

Asparagine synthetase activity in paediatric acute leukaemias: AML‐M5 subtype shows lowest activity

R. Pieters, R. Pieters, H. Müller, 2000, British journal of haematology.

Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia

J. Boos, J. Ritter, U. Creutzig, 1998, Leukemia.

Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol

M. Relling, R. Pieters, M. Valsecchi, 2010, Pediatric blood & cancer.

Enhanced thrombin generation, P-von willebrand factor, P-fibrin D-dimer and P-plasminogen activator inhibitor 1: Predictive for venous thrombosis in asparaginase-treated children

H. Jürgens, J. Boos, U. Nowak‐Göttl, 1994 .

Changes in coagulation and fibrinolysis in childhood acute lymphoblastic leukaemia re-induction therapy using three different asparaginase preparations

H. Jürgens, J. Boos, U. Nowak‐Göttl, 1997, European Journal of Pediatrics.

Pharmacokinetics and Pharmacodynamics of Asparaginase

J. Boos, 1998 .

Loss of activity of Erwinia asparaginase on repeat applications.

H. Jürgens, U. Bode, G. Fleischhack, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscow–Berlin 2002

G. Henze, J. Boos, A. von Stackelberg, 2019, Journal of Cancer Research and Clinical Oncology.

Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL‐BFM treatment protocols

M. Schrappe, G. Hempel, G. Fleischhack, 1999, British journal of haematology.

Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia

J. Boos, P. Schulze-Westhoff, E. Ahlke, 1997, British journal of haematology.

A population pharmacokinetic model for pegylated‐asparaginase in children

C. Lanvers-Kaminsky, G. Hempel, H. Müller, 2010, British journal of haematology.

On the origin of EEG-slowing and encephalopathy during induction treatment of acute lymphoblastic leukemia.

C. Niemeyer, J. Boos, R. Korinthenberg, 2002, Medical and pediatric oncology.

Asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly-diagnosed acute lymphoblastic leukemia

C. Lanvers-Kaminsky, J. Boos, M. Eveslage, 2020, Leukemia & lymphoma.

Asparagine Levels in Children on E. Coli- and Erwinia-Asparaginase Therapy

H. Jürgens, E. Verspohl, J. Boos, 1996 .

Asparaginase Activities In Vitro Are Highly Sensitive to Different Buffer Conditions

H. Jürgens, E. Verspohl, J. Boos, 1997 .

Ethical approval for multicentre clinical trials in children. Contrasting systems in three European countries.

C. R. Pinkerton, J. Boos, T. Philip, 2002, European journal of cancer.

Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines

U. Dirksen, C. Lanvers-Kaminsky, H. Jürgens, 2006, Anti-cancer drugs.

Pharmacokinetics of anticancer drugs in vitro.

G. Hempel, H. Jürgens, J. Boos, 1999, Advances in experimental medicine and biology.

Acute myelogenous leukaemia in children under 2 years--experiences of the West German AML studies BFM-78, -83 and -87. AML-BFM Study Group.

J. Harbott, W. Ludwig, J. Boos, 1992, The British journal of cancer. Supplement.

Inhibition of hypercoagulation by antithrombin substitution in E. coli L‐asparaginase‐treated children

H. Jürgens, J. Boos, U. Nowak‐Göttl, 2009, European journal of haematology.

Oral low‐dose chemotherapy: Successful treatment of an alveolar rhabdomyosarcoma during pregnancy

A. Borkhardt, E. Koscielniak, R. Wessalowski, 2012, Pediatric blood & cancer.

All-trans-retinoic acid increases cytosine arabinoside cytotoxicity in HL-60 human leukemia cells in spite of decreased cellular ara-CTP accumulation.

H. Jürgens, A. Gescher, J. Boos, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study.

D. Frappaz, B. Geoerger, G. Vassal, 2011, European journal of cancer.

Toxicity of Very Prolonged Pegasparaginase and Erwinia Asparaginase Courses in Relation to Asparaginase Activity Levels with a Special Focus on Dyslipidemia

W. Tissing, W. Hop, R. Pieters, 2014 .

No evidence of increased asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy

R. Pieters, C. Lanvers-Kaminsky, J. Boos, 2013, Pediatric blood & cancer.

In-vitro toxicity of Ukrain against human Ewing tumor cell lines

C. Lanvers-Kaminsky, J. Boos, Julia Köster, 2006, Anti-cancer drugs.

Adverse Events During Supervised Exercise Interventions in Pediatric Oncology—A Nationwide Survey

J. Wiskemann, J. Boos, R. Beller, 2021, Frontiers in Pediatrics.

Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.

H. Jürgens, J. Boos, G. Blaschke, 1998, International journal of clinical pharmacology and therapeutics.

Short-term versus continuous infusion: no influence on ifosfamide side-chain metabolism.

H. Jürgens, J. Boos, G. Blaschke, 1995, European journal of cancer.

[Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].

D. Reinhardt, G. Hempel, G. Fleischhack, 2002, Klinische Padiatrie.

Determination of paclitaxel in biological fluids by micellar electrokinetic chromatography.

G. Hempel, J. Boos, G. Blaschke, 1996, Journal of chromatography. A.

Flat-fixed dosing versus body surface area based dosing of anticancer drugs: there is a difference.

G. Hempel, J. Boos, 2007, The oncologist.

Predictive Performance of a Physiologically Based Pharmacokinetic Model of Busulfan in Children

G. Hempel, J. Boos, J. McCune, 2014, Pediatric hematology and oncology.

Pharmacokinetic monitoring of intravenous cyclosporine A in pediatric stem‐cell transplant recipients. The trough level is not enough

K. Welte, L. Grigull, G. Hempel, 2009, Pediatric transplantation.

Modulation of Ara-CToxification by Fludarabine and Hydroxyurea in Leukemic Blasts

J. Boos, C. Rossig, M. Ahlmann, 2001 .

Comparison of Hydroxyurea, Fludarabine and Cladribine in Modulating Ara-C Pharmacology in the Ara-C sensitive and resistant HL-60 and HL-60/Ara-C Cell Lines

H. Jürgens, A. Gescher, J. Boos, 1998 .

Pharmacokinetics of trofosfamide and its dechloroethylated metabolites

H. Jürgens, G. Hempel, J. Boos, 1997, Cancer Chemotherapy and Pharmacology.

Minimization of the Preanalytical Error in Plasma Samples for Pharmacokinetic Analyses and Therapeutic Drug Monitoring - Using Doxorubicin as an Example

A. Boddy, G. Hempel, J. Boos, 2011, Therapeutic drug monitoring.

Risk and benefit from clinical trials in minors: Making the case for transparent and consistent publications

J. Gerss, G. Hempel, J. Boos, 2013 .

Dichloroacetate metabolically targeted therapy defeats cytotoxicity of standard anticancer drugs

C. Lanvers-Kaminsky, U. Karst, J. Boos, 2011, Cancer Chemotherapy and Pharmacology.

Monitoring of N,N-dimethylacetamide in children during i.v.-busulfan therapy by liquid chromatography-mass spectrometry.

G. Hempel, J. Boos, Doris Oechtering, 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Physical activity and childhood cancer

D. Rosenbaum, C. Hoffmann, J. Boos, 2009, Pediatric blood & cancer.

Objectively measured versus self-reported physical activity in children and adolescents with cancer

D. Rosenbaum, J. Boos, S. Kesting, 2017, PloS one.

Experience of barriers and motivations for physical activities and exercise during treatment of pediatric patients with cancer

D. Rosenbaum, J. Boos, C. Winter, 2014, Pediatric blood & cancer.

Comparison of self‐reported physical activity in children and adolescents before and during cancer treatment

D. Rosenbaum, J. Boos, C. Winter, 2014, Pediatric blood & cancer.

Modified total lymphoid irradiation and low dose corticosteroids in progressive multiple sclerosis

J. Goldstein, S. Cook, J. Boos, 1997, Journal of the Neurological Sciences.

Asymmetrical flow field-flow fractionation for the analysis of PEG-asparaginase.

G. Hempel, J. Boos, K. Langer, 2016, Talanta.

Cytotoxic effects of novel polyoxotungstates and a platinum compound on human cancer cell lines

H. Gerth, C. Lanvers-Kaminsky, J. Boos, 2005, Anti-cancer drugs.

MOON-test – Determination of Motor Performance in the Pediatric Oncology

K. Bös, J. Boos, S. Kesting, 2013, Klinische Pädiatrie.

A germ line mutation in cathepsin B points toward a role in asparaginase pharmacokinetics.

R. Kuiper, H. Venselaar, E. Waanders, 2014, Blood.

Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol

M. Zucchetti, M. Schrappe, M. Valsecchi, 2023, HemaSphere.

Hypersensitivity Reactions to Native E. coli L-asparaginase in Children With Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction

B. Burkhardt, M. Schrappe, M. Valsecchi, 2023, HemaSphere.

Therapeutic Drug Monitoring of Asparaginase Activity—Method Comparison of MAAT and AHA Test Used in the International AIEOP-BFM ALL 2009 Trial

M. Zucchetti, J. Gerss, M. Schrappe, 2017, Therapeutic drug monitoring.

The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia

W. Tissing, W. Hop, R. Pieters, 2014, Haematologica.

Vitamin K-dependent coagulation parameters during the first six days of life: incidence of PIVKA II in newborns.

J. Boos, H. Pollmann, H. Dominick, 1989, Pediatric hematology and oncology.

Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data

M. Zucchetti, J. Gerss, M. Schrappe, 2021, European Journal of Drug Metabolism and Pharmacokinetics.

Therapeutic drug monitoring of asparaginase: intra-individual variability and predictivity in children with acute lymphoblastic leukemia treated with PEG-asparaginase in the AIEOP-BFM ALL 2009 study.

M. Zucchetti, J. Gerss, M. Schrappe, 2020, Therapeutic drug monitoring.

Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar® in Children with Acute Lymphoblastic Leukemia

M. Schrappe, M. Karlsson, C. Lanvers-Kaminsky, 2017, European Journal of Drug Metabolism and Pharmacokinetics.

Use of PEG-asparaginase in the treatment of patients with solid tumors

J. Boos, J. P. V. Pinheiro, C. Lanvers, 2001, Cancer Chemotherapy and Pharmacology.

Determination of (E)-5-(2-bromovinyl)-2'-deoxyuridine in plasma and urine by capillary electrophoresis.

G. Hempel, J. Boos, G. Blaschke, 1999, Journal of chromatography. B, Biomedical sciences and applications.

In Vitro Monitoring of Asparaginase: Unphysiological Alteration of the Culture Medium

H. Jürgens, J. Boos, P. Schulze-Westhoff, 1998 .

Impact of Antibodies Against Polyethylene Glycol on the Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukaemia: A Population Pharmacokinetic Approach

C. Lanvers-Kaminsky, G. Würthwein, J. Boos, 2021, European Journal of Drug Metabolism and Pharmacokinetics.

Towards a Model-Based Dose Recommendation for Doxorubicin in Children

N. André, A. Boddy, M. D’Incalci, 2016, Clinical Pharmacokinetics.

Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children

J. Boos, J. Ritter, G. Blaschke, 2004, Cancer Chemotherapy and Pharmacology.

Infusion Rate Does Not Influence Ifosfamide Side-Chain Metabolism

H. Jürgens, J. Boos, G. Blaschke, 1997 .

Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N -dechloroethylation of trofosfamide

H. Kroemer, G. Hempel, J. Boos, 1999, Cancer Chemotherapy and Pharmacology.

High dose therapy versus oral maintenance: Result of HD-CWS 96 study for treatment of patients with metastasized soft tissue sarcoma (STS)

T. Klingebiel, E. Koscielniak, J. Boos, 2006 .

Population pharmacokinetics of dimethylacetamide in children during standard and once-daily IV busulfan administration

Mirjam N Trame, G. Hempel, J. Boos, 2013, Cancer Chemotherapy and Pharmacology.

Development of hypertension in neuroblastoma during therapy: a case report.

A. Roessner, H. Jürgens, J. Boos, 1993, Medical and pediatric oncology.

Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol

M. Zucchetti, M. Schrappe, M. Valsecchi, 2019, Blood.

[Improved treatment results in children with AML: Results of study AML-BFM 93].

F. Berthold, G. Henze, D. Reinhardt, 2001, Klinische Padiatrie.

PEG-Asparaginase in Adult Acute Lymphoblastic Leukemia (ALL): Efficacy and Feasibility Analysis with Increasing Dose Levels

T. Lipp, N. Schmitz, A. Hüttmann, 2008 .

Minimization of the Preanalytical Error in Pharmacokinetic Analyses and Therapeutic Drug Monitoring: Focus on IV Drug Administration

A. Boddy, G. Hempel, G. Würthwein, 2012, Therapeutic drug monitoring.

Drug Monitoring During Maintenance Therapy In Children with ALL

G. Hempel, J. Boos, T. Wessel, 2001 .

[Prognosis of children with acute myelocytic leukemia after first relapse].

J. Boos, J. Ritter, U. Creutzig, 1998, Klinische Padiatrie.

Asparagine Concentration in Plasma After 2 500 IU/m² PEG-Asparaginase i.v. in Children With Acute Lymphoblastic Leukemia

K. Wenner, G. Escherich, J. Boos, 2005, Klinische Padiatrie.

Physical Activity, Exercise and Sports in Young Cancer Patients

J. Boos, S. Kesting, M. Götte, 2020 .

A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.

W. Tissing, M. Relling, W. Hop, 2013, Blood.

Off label use--label off use?

J. Boos, J. Boos, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[HIT-GBM: multicenter study of treatment of children with malignant glioma].

J. Wolff, J. Boos, J. Kühl, 1996, Klinische Padiatrie.

Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials.

J. Gerss, M. Schrappe, G. Henze, 2011, Blood.

Methodological and ethical aspects of randomized controlled clinical trials in minors with malignant diseases

J. Boos, D. Schrey, L. G. Rothenberger, 2011, Pediatric blood & cancer.

Pharmacokinetics and drug monitoring of L-asparaginase treatment.

J. Boos, 1997, International journal of clinical pharmacology and therapeutics.

L‐asparaginase treatment in acute lymphoblastic leukemia

C. Pui, R. Pieters, A. Baruchel, 2011, Cancer.

High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma

M. Cole, C. Challen, J. Lunec, 2010, Clinical Cancer Research.

Methodological and ethical aspects of randomized controlled clinical trials in minors with malignant diseases

J. Boos, D. Schrey, L. G. Rothenberger, 2011, Pediatric blood & cancer.

Pharmacological Aspects of the Oral Application of Etoposide

H. Jürgens, J. Boos, S. Krümpelmann, 1998 .

Resistance to activated protein C (APCR) in children with acute lymphoblastic leukaemia—the need for a prospective multicentre study

B. Dockhorn‐Dworniczak, T. Deufel, H. Jürgens, 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.